Phospho-Noxa (Ser13) (E8I9P) Rabbit mAb #41967
- WB
Supporting Data
REACTIVITY | H |
SENSITIVITY | Transfected Only |
MW (kDa) | 10 |
Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Phospho-Noxa (Ser13) (E8I9P) Rabbit mAb recognizes transfected levels of Noxa protein only when phosphorylated at Ser13. A band of unknown identity is detected at 28 kDa.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Ser13 of human Noxa protein.
Background
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1, Noxa) is a small protein that plays a key role in mediating apoptotic signaling. Noxa is a pro-apoptotic Bcl-2 family protein that contains a single Bcl-2 homology (BH3) domain (1). Members of the “BH3-only” family (e.g., Noxa, Bad, Bim, Puma, Bid, Bik, and Hrk) are highly regulated proteins that induce apoptosis through BH3-dependent interaction with anti-apoptotic Bcl-2 family proteins (2). Noxa localizes to mitochondria and binds the anti-apoptotic proteins Mcl-1 and A1/Bfl-1, but does not bind to Bcl-2 or Bcl-xL (3). The Noxa protein competes with Mcl-1 for binding to mitochondrial Bak protein. Noxa was originally identified as a phorbol ester inducible protein that is highly expressed in adult T-cell leukemia cell lines (4). Several different stimuli, including DNA damage, hypoxia, interferon, viral infection, and double-stranded RNA, induce Noxa expression in cells. Higher levels of Noxa protein are typically found in hematopoietic cells (3,5,6).
Phosphorylation of Noxa at Ser13 by CDK5 was found to inhibit its apoptotic activity (7).
- Ploner, C. et al. (2008) Oncogene 27 Suppl 1, S84-92.
- Bouillet, P. and Strasser, A. (2002) J Cell Sci 115, 1567-74.
- Oda, E. et al. (2000) Science 288, 1053-8.
- Hijikata, M. et al. (1990) J Virol 64, 4632-9.
- Kim, J.Y. et al. (2004) J Exp Med 199, 113-24.
- Sun, Y. and Leaman, D.W. (2005) J Biol Chem 280, 15561-8.
- Lowman, X.H. et al. (2010) Mol Cell 40, 823-33.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.